As the sole provider of
the “PTH Accuratio™ --
1-84 PTH/7-84 PTH ratio”, SCL is
the only laboratory nationwide
to provide both the 1-84 whole
PTH assay value and the 7-84 PTH
inhibitor value, both of which
are critical in the proper
diagnosis and treatment of renal
and bone disease patients.
Published research and bone
histology have clearly
demonstrated the following
points of vital information
regarding PTH:
The parathyroid
glands make two parathyroid
hormones: 1-84 PTH and 7-84
PTH.
1-84 PTH raises bone
turnover.
7-84 PTH lowers bone
turnover.
High bone turnover
disease and adynamic bone
disease are conditions that
are observed histologically,
with bone biopsy being the
gold standard for detecting
and monitoring these
conditions.
An excess of 1-84 PTH
compared to 7-84 PTH causes
high bone turnover disease or
hyperparathyroid bones (HPT).
An excess of 7-84 PTH
compared to 1-84 PTH causes
adynamic bone disease.
Adynamic bone disease
is the most prevalent bone
disease (i.e., it occurs more
often than high bone turnover
disease).
Calcification is
associated with adynamic bone
disease and not with high bone
turnover disease.
Adynamic bone disease IS
REVERSIBLE, but most
calcification is NOT.
Measuring intact PTH
(iPTH -- 1-84 PTH + 7-84 PTH)
will not accurately diagnose
bone turnover nor identify the
majority of patients with
adynamic bone disease.
Measuring only a
single PTH value will not
accurarately diagnose bone
turnover compared to measuring
both 1-84 PTH and 7-84 PTH,
nor will it identify the
majority of patients with
adynamic bone disease.
Only Scantibodies
Clinical Lab (SCL) measures
both 1-84 PTH and 7-84 PTH, to
create the Accuratio™
which does indeed diagnose
adynamic bone disease with 94%
accuracy.
Accurate
determination of bone status
allows the physician to better
manage the Chronic Kidney
Disease (CKD) or End-Stage Renal
Disease (ESRD) patient, as
well as those diagnosed with
hyperparathyroidism or
osteodystrophy.
Better management
information makes it possible
for the physician to
accurately prescribe
therapeutics such as vitamin D
or calcium supplements and to
avoid the serious and often
life-threatening effects of
cardiac calcification,
calcifilaxis (calcium deposits
in the peripheral vasculature)
and other complications.
=
Better quality of life for
renal and bone disease
patients!
(Studies are on file
at Scantibodies to document
each point given above and
also listed in the “references”
section of this site.)
In this website you
will find an introduction to
our laboratory and its
fascinating history
surrounding our breakthrough
in PTH testing. Because SCL is
a dedicated and caring
company, several programs have
been implemented to ensure the
highest quality service to our
customers. Those programs and
a step-by-step guide for
submitting samples and
ordering tests are given
within the SCL Directory of
Services (content of which
appears on this site).
Information for Nephrologists,
Pediatric Nephrologists and
other medical personnel is
given in the Clinical
Information
section. A Patient
Information
section is provided, complete
with glossary, to aid the
renal patient in understanding
his/her disease. Also provided
is a listing of “Upcoming
Events” where our Sales
Representatives will be
available, and more
information about our company
and its opportunities (“Careers”).
We know that you have
many options for choosing a
Clinical Laboratory; but a
working relationship with SCL
means responsive customer
service, innovative 3rd
generation testing with the
PTH Accuratio™ and
accurate, timely reporting.
Each and every employee of the
SCL family is dedicated to
fulfilling the guidelines of
our quality program and
providing superior service.
See our “Contact
Us” section to let us
know how we can help you.
